Much less money is flowing into the sector as venture investors focus on technologies with less risk and easier paths to market. Investment in developers of cell and gene therapies has nosedived this year, a sharp drop-off that investors and analysts say reflect manufacturing and drug delivery challenges at a time when biotechnology companies with clear development paths are increasingly favored.